Optimizing Stroke Prevention in Nonvalvular Atrial Fibrillation (NVAF): What Do the Results of Landmark Clinical Trials with Factor Xa and DT Inhibitors Teach Us? Where Are the Guidelines and Risk Stratification Tools Directing Us? How Do We Match Specific AF Patients with Specific NOACs? - Christian T. Ruff, MD – Program Co-Chairman